The evaluation of women with schizophrenia

Psychopharmacology Bulletin

Volumn 34, Issue 3, 1998, Pages 271-277

  Canuso, Carla M ^a,b   Goldstein, Jill M ^a,b   Green, Alan I ^a,b  

^a MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Evaluation; Hyperprolactinemia; Schizophrenia; Sex differences; Women

Indexed keywords

ESTRADIOL; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROLACTIN;

COMORBIDITY; CONFERENCE PAPER; CONTRACEPTION; DRUG RESPONSE; FEMALE; HOMELESSNESS; HUMAN; HYPERPROLACTINEMIA; MOTHER; PREGNANCY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; SUICIDE; VICTIM;

FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WOMEN;

EID: 0031792576     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (78)

1. Abraham, G; Friedman, RH; Verghese, C; and de Leon, J. Osteoporosis and schizophrenia: Can we limit known risk factors? Biol. Psychiatry 38:131-132, 1995.
2. Alvir, JMJ, and Lieberman, JA. Angranulocytosis: Incidence and risk factors. J. Clin. Psychiatry 55(Suppl. 9B):137-138, 1994.
3. Andreasen, NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983.
4. Angermeyer, MC; Goldstein, JM; and Kuhn, L. Gender differences in schizophrenia: Rehospitalization and community survival. Psychol. Med. 19:365-382, 1989.
5. Angermeyer, MC, and Kuhn, L. Gender differences in age at onset of schizophrenia. Eur. Arch. Psychiatry Neurol. Sci. 237:351-364, 1988.
6. Angermeyer, MC; Kuhn, L; and Goldstein, JM. Gender and the course of schizophrenia: Differences in treated outcomes. Schizophr. Bull. 16(2):293-307, 1990.
7. Apfel, RJ, and Handel, MH. Madness and Loss of Motherhood: Sexuality, Reproduction, and Long-Term Mental Illness. Washington, DC: APA Press, 1993.
8. Aylward, E; Walker, E; and Bettes, B. Intelligence in schizophrenia. Schizophr. Bull. 10(3):430-459, 1984.
9. Beasley, CM; Tollefson, G; Tran, P; Satterlee, W; Sanger, T; Hamilton, S; and the HGAD Study Group. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol. 14:111-123, 1996.
10. Canuso, CM; Hanau, M; Jhamb, KJ; and Green, AI. Olanzapine use in women with antipsychotic-induced hyperprolactinemia. Am. J. Psychiatry, in press.
11. Caton, CL; Shrout, PE; Dominguez, B; Eagle, PF, Opler, LA; and Cournos, F. Risk factors for homelessness among women with schizophrenia. Am. J. Public Health 85(8):1153-1156, 1995.
12. Chouinard, G, and Annable, L. Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology 76:13-19, 1982.
13. Chouinard, G; Annable, L; Ross-Chouinard, A; and Nestoruos, JN. Factors related to tardive dyskinesia. Am. J. Psychiatry 136:79-83, 1979.
14. Cohen, LS; Goldstein, JM; Lee, H; Tohen, M; Andersen, M; and Tollefson, GD. "Sex and neuroendocrine differences in response to treatment with olanzapine: A preliminary analysis." Presented at the New Clinical Drug Evaluation Unit Conference, Boca Raton, FL, May, 1997.
15. de Leon, J; Dadvand, M; Canuso, C; White, AO; Stanilla, JK; and Simpson, GM. Schizophrenia and smoking: An epidemiological survey in a state hospital. Am. J. Psychiatry 152:453-455, 1995.
16. Dickson, RA; Dalby, JT; Williams, R; and Edwards, A. Risperidone-induced prolactin elevations in premenopausal woman with schizophrenia. Am. J. Psychiatry 152(7):1102-1103, 1995.
17. Dickson, RA, and Edwards, A. Clozapine and fertility. Am. J. Psychiatry 154:582-583, 1997.
18. Drake, RE, and Wallach, MA. Substance abuse among the chronically mentally ill. Hosp. Comm. Psychiatry 40(10):1041-1046, 1989.
19. Eaton, WW; Day, R; and Morton, K. The use of epidemiology for risk factor research in schizophrenia: An overview and methodologic critique. In: Tsuang, MT, and Simpson, JC, eds. Handbook of Schizophrenia (Volume 3): Nosology, Epidemiology, and Genetics of Schizophrenia. Amsterdam: Elsevier Press, 1988. pp. 169-204.
20. Erlenmeyer-Kimling, L; Kestenbaum, C; Bird, H; and Hilldoff, U. Assessment of the New York high-risk project subjects in sample A who are now clinical deviants. In: Watt, N; Anthony, EJ; Wynne, LC; and Rolf, JE, eds. Children at Risk for Schizophrenia: A Longitudinal Prospective. Cambridge, MA: Cambridge University Press, 1984.
21. First, MB; Spitzer, RL; Gibbon, M; and Williams, JBW. Structured Clinical Interview for DSM-IV. Washington, DC: APA Press, 1996.
22. Glick, M; Mazure, CM; Bowers, MB; and Zigler, E. Premorbid social competence and the effectiveness of early neuroleptic treatment. Compr. Psychiatry 34:396-401, 1993.
23. Goldstein, JM. Gender differences in the course of schizophrenia. Am. J. Psychiatry 145:684-689, 1988.
24. Goldstein, JM. Sampling biases in studies of gender and schizophrenia: A reply. Schizophr. Bull. 19(1):9-14, 1993.
25. Goldstein, JM. The impact of gender on understanding the epidemiology of schizophrenia. In: Seeman, MV, ed. Gender and Psychopathology. Washington, DC: APA Press, 1995.
26. Goldstein, JM. Sex and brain abnormalities in schizophrenia: Fact or fiction? Harvard Rev. Psychiatry 4:110-115, 1996.
27. Goldstein, J, and Link, B. Gender and the expression of schizophrenia. J. Psychiatr. Res. 22(2):141-155, 1988.
28. Goldstein, JM; Santangelo, SL; Simpson, J; and Tsuang, MT. Gender and mortality in schizophrenia: Do women act like men? Psychol. Med. 23:941-948, 1993.
29. Goodman, LA; Dutton, MA; and Harris, M. Episodically homeless women with serious mental illness: Prevalence of physical and sexual assault. Am. J. Orthopsychiatry 65(4):468-478, 1995.
30. Green, AI, and Brown, WA. Prolactin and neuroleptic drugs. Neurol. Clin. 6(1):21-223, 1988.
31. Guy, W, ed. Abnormal Involuntary Movement Scale. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976. pp. 534-537.
32. Hafner, H; Behnens, S; Devry, J; and Gattaz, WF. An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia. Psych. Res. 38:125-134, 1991.
33. Halbreich, U, and Palter, S. Accelerated osteoporosis in psychiatric patients: Possible pathophysiology processes. Schizophr. Bull. 22:447-454, 1996.
34. Halbreich, U; Shen, J; and Panaro, V. Are chronic psychiatric patients at increased risk for developing breast cancer? Am. J. Psychiatry 153:559-560, 1996.
35. Halloquist, J; Seeman, M; Lang, M; and Rector, N. Variations in symptom severity over the menstrual cycle of schizophrenics. Biol. Psychiatry 33:207-209, 1993.
36. Harkavy-Friedman, JM, and Nelson, E. Management of the suicidal patient with schizophrenia. Psychiatr. Clin. North Am. 20(3):625-640, 1997.
37. Hoff, AL; Wieneke, M; Horon, R; Blankfeld, H; Espinoza, S; Faustman, WO; Kremen, WS; and Nordahl, T. Estrogen levels relate to neuropsychological function in female schizophrenics. Schizophr. Res. 24:107-108, 1997.
38. Jacobson, R. Alcohol dependence in women: Early onset of brain damage. Br. J. Hosp. Med. 39(6):476, 1988.
39. Josiassen, RC, and Schindler, B. Medical comorbidity and schizophrenia: Editors' introduction. Schizophr. Bull. 22(3):411-412, 1996.
40. Kando, JC; Yonkers, KA; and Cole, JO. Gender as a risk factor for adverse events to medications. Drugs 50(1):1-6, 1995.
41. Kane, JM; Cooper, TB; Sacher, EJ; Halpern, FS; and Bailine, S. Clozapine: Plasma levels and prolactin response. Psychopharmacology 73:184-187, 1981.
42. Kelly, JA; Murphy, DA; Bahr, GR; Brasfield, TL; Davis, DR; Hauth, AC; Morgan, MG; Stevenson, LY; and Eilers, MK. AIDS/HIV risk behavior among the chronically mentally ill. Am. J. Psychiatry 149(7):886-889, 1992.
43. Lewine, RRJ. Sex differences in schizophrenia: Timing or subtype? Psychol. Bull. 90:432-444, 1981.
44. Lewine, RR. Gender and schizophrenia. In: Tsuang, MT, and Simpson, JC, eds. Handbook of Schizophrenia (Volume 3): Nosology, Epidemiology, and Genetics of Schizophrenia. Amsterdam: Elsevier Press, 1988. pp. 379-397.
45. Lewine, RRJ, and Seeman, MV. Gender, brain and schizophrenia: Anatomy of differences/differences of anatomy. In: Seeman, MV, ed. Gender and Psychopathology. Washington, DC: APA Press, 1995.
46. Loebel, AD; Lieberman, JA; Alvir, JMA; Geisler, SH; and Szymanski, SR. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry 149:1183-1188, 1992.
47. Mayfield, D; McLeod, G; and Hall, P. The CAGE Questionnaire: Validation of a new alcoholism screening instrument. Am. J. Psychiatry 131:1121-1123, 1974.
48. Mednick, SA; Schulsinger, F; Teasdale, TW; Schulsinger, H; Venables, PH; and Rock, DR. Schizophrenia in high risk children: Sex differences in predisposing factors. In: Serban, G, ed. Cognitive Defects in the Development of Mental Illness. New York: Brunner/Mazel, 1978. pp. 169-197.
49. Meltzer, HY. Long-term effects of neuroleptic drugs on the neuroendocrine system. In: Kremali, D, and Racagni, G, eds. Chronic Treatments in Neuropsychiatry: Advances in Biochemical Psychopharmacology. New York: Raven Press, 1985. pp. 59-58.
50. Meltzer, HY; Busch, DA; and Fang, VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res. 9:271-283, 1983.
51. Mortola, JF. The use of psychotropic agents in pregnancy and lactation. Psychiatry Clin. North Am. 12(1):69-87, 1989.
52. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
53. Overall, JE, and Gorham, DE. The Brief Psychiatric Rating Scale. Psychol Rep. 10:799-812, 1962.
54. Paganini-Hill, A. The risks and benefits of estrogen replacement therapy: Leisure world. Int. J. Fertil. Menopausal Stud. 40(Suppl. 1):54-62, 1995.
55. Pinals, DA; Malhotra, AK; Missar, CD; Pickar, D; and Breier, A. Lack of gender difference in neuroleptic response in patients with schizophrenia. Schizophr. Res. 22:215-222, 1996.
56. Rector, NA, and Seeman, MV. Auditory hallucinations in women and men. Schizophr. Res. 7:233-236, 1992.
57. Reicher-Rossler, A; Hafner, H; Sternbaum, M; Maurer, K; and Schmidt, R. Can estradiol modulate schizophrenic symptomatology? Schizophr. Bull. 20(1):201-214, 1994.
58. Regier, DA; Farmer, ME; Rae, DS; Locke, BZ; Keith, SJ; Judd, LL; and Goodwin, FK. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiological Catchment Area Study. JAMA 264:2511-2518, 1990.
59. Salokangas, RKR. Prognostic implications of the sex of schizophrenic patients. Br. J. Psychiatry 142:145-151, 1983.
60. Seeman, MV. Interaction of sex, age, and neuroleptic dose. Compr. Psychiatry 24:125-128, 1983.
61. Seeman, MV. Current outcome in schizophrenia: Women vs men. Acta Psychiatr. Scand. 73:609-617, 1986.
62. Seeman, MV. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 21:123-127, 1996.
63. Seeman, MV. Psychopathology in women and men: Focus on female hormones. Am. J. Psychiatry 154(12):1641-1647, 1997.
64. Seeman, MV, and Lang, M. The role of estrogens in schizophrenia gender differences. Schizophr. Bull. 16:185-194, 1990.
65. Shenfield, GM, and Griffen, JM. Clinical pharmacokinetics of contraceptive steroids: An update. Clin. Pharmacokinet. 20:15-37, 1991.
66. Simpson, GM; Yadalam, KG; Levison, DF; Stephanos, MJ; Sing Lo, EE; and Cooper, TB. Single dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J. Clin. Psychopharmacol. 10:417-421, 1990.
67. Simpson, JC, and Tsuang, MT. Mortality among patients with schizophrenia. Schizophr. Bull. 22(3):485-499, 1996.
68. Skinner, HA. The Drug Abuse Screening Test. Addict. Behav. 7(4):363-371, 1982.
69. Stewart, DE, and Gangbar, R. Psychiatric assessment of competency to care for a new born. Can. J. Psychiatry 29:583-589, 1984.
70. Szymanski, S; Lieberman, JA; Alvir, JM; Mayerhoff, D; Loebel, A; Geisler, S; Chackos, M; Koreen, A; Jody, D; Kane, J; Woerner, M; and Cooper, T. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry 152(5):698-703, 1995.
71. Szymanski, S; Lieberman, J; Pollack, S; Kane, JM; Safferman, A; Munne, R; Umbricht, D; Woerner, M; Masiar, S; and Kronig, M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol. Psychiatry 39:249-254, 1996.
72. Trixler, M; Gati, A; and Tenyi, T. Risks associated with childbearing in schizophrenia. Acta Psychiatr. Belg. 95(3):159-162, 1995.
73. Virgona, A; Buhrich, N; and Teesson, M. Prevalence of schizophrenia among women in refuges for the homeless. Aust. NZ J. Psychiatry 27(3):405-410, 1993.
74. Weissman, M. "Sex differences in the rates of mental disorders." Paper presented at the Institute of Medicine's Conference Assessing Future Research Needs: Mental and Addictive Disorders in Women. Washington, DC, May, 1991.
75. Wetzel, H; Szegedi, A; Hain, C; Wiesner, J; Schlegel, S; and Benkert, O. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: Results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119(2):231-238, 1995.
76. Yazigi, RA; Quintero, CH; and Salameh, WA. Prolactin disorders. Fertil. Steril. 67:215-225, 1997.
77. Yonkers, KA; Kando, JC; Cole, JO; and Blumenthal, S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry 149(5):587-595, 1992.
78. Yonkers, KA; Kando, JC; and Hamilton, J. Gender issues in psychopharmacologic treatment. Directions in Psychiatry 15:1-8, 1995.